2 ms·
"I use to work in pharma research (at the data acquisition and analysis side, blinded from treatment) and the fact that pharmas are able to start clinical trial
by marincounty 11y ago
"I use to work in pharma research (at the data acquisition and analysis side, blinded from treatment) and the fact that pharmas are able to start clinical trials and then shut them down without reporting result is a problem."
This Cherry Picking should become a felony? Spit out the data you have on hand, even if incomplete? Give the results of the studies to the FDA, or make whatever data you have available to the scientific community at large?
Why don't they make this information available; because usually the study didn't prove their hypothesis, and they need to start another study hoping the data just might magically change? And with the right 3rd party researchers, in the right foreign countries--poof the data magically seems to turn around? And the company has a new money maker?
- joesmo 11y agoYes.
- acveilleux 11y agoSo sometimes, the population of a trial does not show efficacy but some subgroup does. Like folks with a different gene, a different stage in the disease, etc. Frequently those sub-populations lack statistical power. So then a new trial will be made targeting that sub-population if it looks promising enough (i.e.: cost vs. potential benefit/market size). Is that a bad thing? It's variable whether the study that failed to get statistical results will get published and if so, how. The legally required filings with the FDA are done in any case.